Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
BMJ Case Rep ; 17(9)2024 Sep 26.
Article in English | MEDLINE | ID: mdl-39327035

ABSTRACT

This case report outlines the diagnostic and therapeutic challenges encountered in a man in his 70s suffering from knee septic arthritis caused by Aspergillus niger It is the second published case in the literature with osteoarticular infection from A. niger and the first one in the last 40 years. Following knee arthroscopy, the patient experienced persistent pain, swelling and discomfort, prompting further investigation. Postoperative knee cultures were negative for infection, but symptoms were not ameliorated. Therefore, an arthroscopic debridement was performed that revealed severe joint inflammation and degeneration. Cultures from the synovial fluid and tissue samples identified infection from A. niger sp. Antimicrobial treatment with voriconazole finally led to significant clinical improvement and eradication of infection. This case highlights the intricacies involved in diagnosing and managing fungal osteoarticular infections in healthy patients without concomitant medical diseases or comorbidities.


Subject(s)
Antifungal Agents , Arthritis, Infectious , Arthroscopy , Aspergillosis , Aspergillus niger , Debridement , Knee Joint , Humans , Arthritis, Infectious/microbiology , Arthritis, Infectious/diagnosis , Male , Aspergillus niger/isolation & purification , Knee Joint/microbiology , Knee Joint/surgery , Antifungal Agents/therapeutic use , Debridement/methods , Aged , Aspergillosis/diagnosis , Aspergillosis/microbiology , Aspergillosis/drug therapy , Voriconazole/therapeutic use , Postoperative Complications/microbiology , Postoperative Complications/diagnosis
2.
Cureus ; 16(7): e65112, 2024 Jul.
Article in English | MEDLINE | ID: mdl-39171000

ABSTRACT

Mycobacterium abscessus is a difficult-to-treat, multidrug-resistant human pathogen. Relebactam has been shown to inhibit M. abscessus ß-lactamase (BLAMab) and increase the activity of imipenem and amoxicillin. We present two cases of lung infection due to M. abscessus, one caused by M. abscessussubsp. massiliense and the other by subsp. abscessus. Both strains showed moderate sensitivity to imipenem, and the second strain was also resistant to macrolides. A multidrug antibiotic regimen was administered in both cases, which included imipenem/cilastatin/relebactam adjusted to the estimated glomerular filtration rate (eGFR) and amoxicillin for three months. The regimen was well tolerated and both patients improved both clinically and radiologically after the first phase of treatment. The results of our patients indicate that the combination of imipenem/cilastatin/relebactam and amoxicillin could be used in the future in difficult infections by M. abscessus.

3.
Future Microbiol ; 19(13): 1119-1127, 2024 Sep.
Article in English | MEDLINE | ID: mdl-38913938

ABSTRACT

Aim: The aim was to highlight the incidence and epidemiology of C. difficile infections (CDI) in a tertiary Greek hospital during the COVID-19 pandemic.Methods: A single-center prospective observational cohort study was conducted (October 2021 until April 2022). 125 C. difficile isolates were cultured from hospitalized patients stool samples and screened by PCR for toxin A (tcdA), toxin B (tcdB), binary toxin (cdtA and cdtB) genes and the regulating gene of tcdC.Results: The incidence of CDI increased to 13.1 infections per 10,000 bed days. The most common PCR ribotypes identified included hypervirulent RT027-related RT181 (73.6%), presumably hypervirulent RT126 (8.0%) and toxin A negative RT017 (7.2%).Conclusion: Although the incidence of CDI increased significantly, the CDI epidemiology remained stable.


[Box: see text].


Subject(s)
COVID-19 , Clostridioides difficile , Clostridium Infections , Humans , Greece/epidemiology , COVID-19/epidemiology , Clostridioides difficile/genetics , Clostridioides difficile/isolation & purification , Clostridioides difficile/classification , Clostridium Infections/epidemiology , Clostridium Infections/microbiology , Prospective Studies , Male , Female , Incidence , Aged , Middle Aged , Ribotyping , Feces/microbiology , Feces/virology , SARS-CoV-2/genetics , SARS-CoV-2/isolation & purification , Aged, 80 and over , Adult , Bacterial Toxins/genetics , Bacterial Proteins/genetics , Pandemics , Tertiary Care Centers/statistics & numerical data , Enterotoxins/genetics
4.
Med Mycol ; 62(7)2024 Jul 04.
Article in English | MEDLINE | ID: mdl-38877671

ABSTRACT

Candida auris is an emerging fungal pathogen associated with multi-drug resistance rates and widespread outbreaks in hospitals and healthcare units worldwide. Sequencing studies have revealed that different clonal lineages of the fungus seem to be prevalent among distinct geographical sites. The first case of C. auris in Northern Greece was reported in Thessaloniki in October 2022, almost 2 years after the first isolation in Greece (Athens 2019). The Mycology Laboratory of the Medical School of Aristotle University of Thessaloniki stands as the reference laboratory for fungal diseases in Northern Greece and a meticulous search for the yeast, in plenty of suspicious samples, has been run since 2019 in the Lab as well as a retrospective analysis of all its yeasts' collection, back to 2008, with negative results for the presence of C. auris. Here, are presented the findings concerning the outbreak and surveillance of C. auris in Northern Greece, mainly the region of Thessaloniki and the broader area of Macedonia, from October 2022 until August 2023. The isolates from Northern Greece continue to fall in Clade I and present with an almost equal and stable sensitivity profile until now.


The study concerns the outbreak of Candida auris in Northern Greece since October 2022 and the effort for surveillance and epidemiological monitoring. All isolates continue to fall in Clade I and present with an almost equal and stable sensitivity profile till now.


Subject(s)
Candida auris , Candidiasis , Disease Outbreaks , Epidemiological Monitoring , Greece/epidemiology , Humans , Candidiasis/epidemiology , Candidiasis/microbiology , Candida auris/genetics , Candida auris/isolation & purification , Retrospective Studies , Antifungal Agents/pharmacology , Microbial Sensitivity Tests , Male , Drug Resistance, Multiple, Fungal , Candida/isolation & purification , Candida/classification , Candida/genetics , Female
5.
Microorganisms ; 11(7)2023 Jul 13.
Article in English | MEDLINE | ID: mdl-37512971

ABSTRACT

Skin and soft tissue infections caused by non-tuberculous mycobacteria are occurring more frequently in recent years. However, chronic skin and soft tissue lesions present a challenge for clinicians, as the diagnostic work-up and definitive diagnosis require knowledge and available laboratory resources. We present here the case of a 66-year-old male patient who presented with painful abscess-like nodules on his right hand and forearm, which worsened after treatment with an anti-TNF-a agent. The fluid specimen taken from the lesion was positive for mycobacteria according to the acid-fast stain. Mycobacterium marinum was identified, first by next-generation sequencing and finally grown on culture, after eight weeks. Acknowledging the complexity of diagnosing and managing infections by non-tuberculous mycobacteria, and especially Mycobacterium marinum, we provide a review of the current epidemiology, clinical characteristics, diagnosis and management of Mycobacterium marinum infection.

6.
J Med Microbiol ; 72(5)2023 May.
Article in English | MEDLINE | ID: mdl-37195744

ABSTRACT

Introduction. C. difficile infection (CDI) represents an important global threat. In the COVID-19 era, the multifactorial nature of CDI has emerged.Hypothesis - Aim. The aim was to assess the impact of COVID-19 pandemic on the incidence of CDI in a Greek hospital.Methodology. A retrospective study was performed throughout a 51 month period (January 2018 to March 2022), divided into two periods: pre-pandemic (January 2018 to February 2020) and COVID-19 pandemic (March 2020 to March 2022). The effects of the pandemic compared to the pre-pandemic period on the incidence of CDI [expressed as infections per 10 000 bed days (IBD)] were studied using interrupted time-series analysis.Results. Throughout the study, there was an increase in the monthly CDI incidence from 0.00 to 11.77 IBD (P<0.001). Interrupted time-series disclosed an increase in CDI incidence during the pre-pandemic period from 0.00 to 3.36 IBD (P<0.001). During the COVID-19 pandemic period the linear trend for monthly CDI rose from 2.65 to 13.93 IBD (P<0.001). The increase rate was higher during the COVID-19 pandemic period (r2 = +0.47) compared to the pre-pandemic period (r1 = +0.16).Conclusion. A significant increase of CDI incidence was observed, with the rate of the rise being more intense during the COVID-19 pandemic.


Subject(s)
COVID-19 , Clostridioides difficile , Clostridium Infections , Cross Infection , Humans , COVID-19/epidemiology , Pandemics , Retrospective Studies , Tertiary Care Centers , Incidence , Greece/epidemiology , Clostridium Infections/epidemiology , Cross Infection/epidemiology
7.
Nutrients ; 15(6)2023 Mar 08.
Article in English | MEDLINE | ID: mdl-36986061

ABSTRACT

BACKGROUND: Gut microbiota is well-known for its ability to maintain intestinal homeostasis. However, the disruption of this homeostasis, known as dysbiosis, leads to multiple consequences, including local and systemic inflammation. Surgery-induced inflammation is a major concern for patients, as it leads to many infectious and non-infectious complications. OBJECTIVE: The purpose of this review was to explore the role of probiotics and symbiotics in surgery-induced inflammation and to determine if their use is effective in combatting inflammation and its complications Methods and Materials: A literature search was conducted, and articles published only in English, until December 2022 were included. The results are reported in the form of a narrative review. RESULTS: The perioperative use of probiotics and/or symbiotics results in lower risk of infectious complications, including reduced rates of surgical site infections, respiratory and urinary tract infections, shorter hospital stays, and fewer days of antibiotic administration. It also contributes to reducing non-infectious complications, as it mitigates systemic and local inflammation via maintenance of the intestinal barrier, improves intestinal mobility, and is associated with lower rates of postoperative pain and anastomotic leak. CONCLUSIONS: Restoring gut microbiota after disruptions caused by surgery may accelerate local healing processes, attenuate systemic inflammation, and may thus prove beneficial to certain populations.


Subject(s)
Gastrointestinal Microbiome , Probiotics , Humans , Inflammation , Intestines , Dysbiosis
8.
Yale J Biol Med ; 95(4): 479-494, 2022 12.
Article in English | MEDLINE | ID: mdl-36568836

ABSTRACT

Background: The importance of gut microbiota in human health is being increasingly studied. Imbalances in gut microbiota have been associated with infection, inflammation, and obesity. Antibiotic use is the most common and significant cause of major alterations in the composition and function of the gut microbiota and can result in colonization with multidrug-resistant bacteria. Methods: The purpose of this review is to present existing evidence on how microbiota modulation and prevention of gut dysbiosis can serve as tools to combat antimicrobial resistance. Results: While the spread of antibiotic-resistant pathogens requires antibiotics with novel mechanisms of action, the number of newly discovered antimicrobial classes remains very low. For this reason, the application of alternative modalities to combat antimicrobial resistance is necessary. Diet, probiotics/prebiotics, selective oropharyngeal or digestive decontamination, and especially fecal microbiota transplantation (FMT) are under investigation with FMT being the most studied. But, as prevention is better than cure, the implementation of antimicrobial stewardship programs and strict infection control measures along with newly developed chelating agents could also play a crucial role in decreasing colonization with multidrug resistant organisms. Conclusion: New alternative tools to fight antimicrobial resistance via gut microbiota modulation, seem to be effective and should remain the focus of further research and development.


Subject(s)
Gastrointestinal Microbiome , Probiotics , Humans , Anti-Bacterial Agents/pharmacology , Dysbiosis/drug therapy , Dysbiosis/microbiology , Drug Resistance, Bacterial , Probiotics/pharmacology , Probiotics/therapeutic use , Fecal Microbiota Transplantation
9.
Front Med (Lausanne) ; 7: 157, 2020.
Article in English | MEDLINE | ID: mdl-32478082

ABSTRACT

Introduction: Medicine shortages result in great risk for the continuity of patient care especially for antimicrobial treatment, potentially enhancing resistance rates and having a higher economic impact. This study aims to identify, describe, assess, and assign risk priority levels to potential failures following substitution of antimicrobial treatment due to shortages among European hospitals. Furthermore, the study investigated the impact of corrective actions on risk reduction so as to provide guidance and improve future patient care. Methods: Health-care failure mode and effect analysis (HFMEA) was applied to hospitals in Austria (H-AT), Belgium (H-BE), Croatia (H-CR), Greece (H-GR), Spain (H-SP), and Serbia (H-SR). Multidisciplinary teams identified processes, failure modes, causes, and corrective actions related to antibiotic substitution following medicine shortages. Characteristics of study hospitals as well as severity, probability, and hazard scores (HSs) of failure modes/causes were analyzed using Microsoft Office Excel 2010 and IBM SPSS Statistics® via descriptive and inferential statistics. Results: Through HFMEA, 74 failure modes were identified, with 53 of these scoring 8 or above on the basis of assigned severity and probability for a failure. Severity of failure modes differed before and after corrective actions in H-CR, H-GR, and H-SR (p < 0.005). Their probability differed in all study hospitals (p < 0.005) when compared before and after corrective actions aimed to be implemented. The highest number of failure-mode causes was detected in H-CR (46) and the lowest in H-SP (16). Corrective actions can address failure modes and lower HSs; therein, all teams proposed the following: structuring communication among stakeholders, introducing electronic prescribing, strengthening pharmacists' involvement, and increasing effectiveness of the ward stock assessment. These proposed actions led to HS reductions up to 83%. Conclusion: There is a lack of structure in addressing risks associated with antibiotic substitution following shortages. Furthermore, lack of communication, data scarcity on availability of antibiotics, non-supportive information technology (IT) systems, and lack of internal substitution protocols hinder quick assessment of alternatives addressing patient needs. Nevertheless, the study shows that health-care professionals manage to secure optimal antimicrobial treatment for patients using available IT and human resources.

SELECTION OF CITATIONS
SEARCH DETAIL